The Centers for Medicare & Medicaid Services (CMS) has issued a Final Rule that advances policies for the Medicaid Drug Rebate Program (MDRP).
Under the MDRP, drug manufacturers are required to report various product and pricing details, including whether a drug is classified as brand-name or generic. This classification is crucial, because it determines the rebate amounts manufacturers owe to states. Brand-name drugs have higher rebate rates than generic drugs.
The new rule introduces statutory provisions to address incorrect reporting and misclassification of drugs in the Medicaid Drug Program (MDP) system. Manufacturers will be obligated to correct any misclassification and pay any unpaid rebates resulting from the incorrect reporting. If manufacturers fail to correct these issues, CMS has several enforcement options, including suspending the drug from Medicaid payments, imposing civil penalties, or terminating the manufacturer from the MDRP.
The rule also allows CMS to suspend a manufacturer’s National Drug Rebate Agreement for at least 30 days if drug pricing and product information is reported late.
The Final Rule includes several provisions to improve the overall efficiency of the MDRP. One significant update is the definition of the “market date” for a drug, which will be used to calculate inflation rebates. This is critical for ensuring that manufacturers pay the correct rebates on their covered outpatient drugs (CODs). Another provision limits the period in which manufacturers can dispute state-invoiced utilization data to 12 quarters, ensuring timely resolution of rebate-related disputes.
Additionally, the rule specifies that Medicaid Fee-for-Service (FFS) reimbursement for both drug ingredients and dispensing fees must be based on pharmacy-established cost data. It also requires states to collect National Drug Code (NDC) information on all physician-administered drugs, ensuring that these drugs are included in the rebate process and that states receive the proper federal matching funds.
The rule further refines the definition of a COD to include drugs that are reimbursed as part of an inclusive payment, such as bundled services. This ensures that drugs reimbursed in this way are properly accounted for in the rebate system. Additionally, it clarifies the conditions under which manufacturers can update pricing data outside the 12-quarter window, allowing for more accurate reporting.
Since more than 75 percent of Medicaid beneficiaries receive care through managed care plans, the rule addresses several important aspects of pharmacy benefits in Medicaid managed care. CMS now requires that states, through their managed care contracts, instruct Medicaid managed care plans to use a Medicaid-specific Bank Identification Number (BIN) and Processor Control Number (PCN) on beneficiaries’ cards. This change is designed to prevent duplicate discounts in the 340B Drug Discount Program and to ensure the appropriate delivery of benefits.
The rule also introduces transparency requirements for managed care contracts with pharmacy benefit managers (PBMs). PBMs often use spread pricing, where they retain the difference between what the plan pays and what they reimburse the pharmacy. The new requirements will make these pricing practices more transparent to the states and beneficiaries.
Several additional provisions in the rule align with recent legislative changes. The American Rescue Plan Act of 2021 removed the 100-percent cap on Medicaid drug rebates, effective Jan. 1, 2024. As a result, CMS has included a sunset date of Dec. 31, 2023 for the average manufacturer price (AMP) cap on Medicaid drug rebates in the regulatory text.
The rule also conforms to a court decision regarding PBM accumulator programs, rescinding changes made by a 2020 rule that revised how best prices and AMP are determined under Medicaid. This action complies with a court order that vacated the 2020 rule’s “Accumulator Adjustment Rule.”
Finally, the rule modifies third-party liability rules to correct an oversight in prior regulations. These changes are consistent with statutory provisions from the Bipartisan Budget Act of 2018, which allowed states to “pay and chase” for certain services, improving the coordination of benefits under Medicaid.
Previously neuroendocrine tumors (NETs) were called carcinoid tumors and some clinicians will continue to call them carcinoid tumors. This is a physician query opportunity. They
If you’ll recall, a couple of weeks ago, I reported on the Centers for Medicare & Medicaid Services (CMS) Proposed Rule for the social determinants
Please log in to your account to comment on this article.
Optimize your outpatient clinical documentation and gain comprehensive knowledge from foundational practices to advanced technologies, ensuring improved patient care and organizational and financial success. This webcast bundle provides a holistic approach to outpatient CDI, empowering you to implement best practices from the ground up and leverage advanced strategies for superior results. You will gain actionable insights to improve documentation quality, patient care, compliance, and financial outcomes.
Enhancing outpatient clinical documentation is crucial for maintaining accuracy, compliance, and proper reimbursement in today’s complex healthcare environment. This webcast, presented by industry expert Angela Comfort, DBA, RHIA, CDIP, CCS, CCS-P, will provide you with actionable strategies to tackle complex challenges in outpatient documentation. You’ll learn how to craft detailed clinical narratives, utilize advanced EHR features, and implement accurate risk adjustment and HCC coding. The session also covers essential regulatory updates to keep your documentation practices compliant. Join us to gain the tools you need to improve documentation quality, support better patient care, and ensure financial integrity.
This webcast, presented by Angela Comfort, DBA, RHIA, CDIP, CCS, CCS-P, a recognized expert with over 30 years of experience, offers essential strategies to improve outpatient clinical documentation integrity. You will learn how to enhance the accuracy and completeness of patient records by adopting best practices in coding and incorporating Social Determinants of Health (SDOH). The session also highlights the role of technology, such as EHRs and CDI software, in improving documentation quality. By attending, you will gain practical insights into ensuring precise and compliant documentation, supporting patient care, and optimizing reimbursement. This webcast is crucial for those looking to address documentation gaps and elevate their coding practices.
ICD10monitor has teamed up with renowned CDI expert Dr. Erica Remer to bring you an exclusive webcast on how to recognize sepsis, how to get providers to give documentation that will support sepsis, and how to educate to avert sepsis denials. Register now and become a crucial piece of the solution to standardizing sepsis clinical practice, documentation, and coding at your facility.
Protect your facility from unwanted audits! Join Becky Jacobsen, BSN, RN, MBS, CCS-P, CPC, CPEDC, CBCS, CEMC, and take a deep dive into both the CMS and AMA guidelines for reporting post operative pain blocks. You’ll learn how to determine if the nerve block is separately codable with real life examples for better understanding. Becky will also cover how to evaluate whether documentation supports medical necessity, offer recommendations for stronger documentation practices, and provide guidance on educating providers about documentation requirements. She’ll include a discussion of appropriate modifier and diagnosis coding assignment so that you can be confident that your billing of post operative pain blocks is fully supported and compliant.
During this RACmonitor webcast Dr. Ronald Hirsch spotlights the areas of the OIG’s Work Plan and the findings of their most recent audits that impact utilization review, case management, and audit staff. He also provides his common-sense interpretation of the prevailing regulations related to those target issues. You’ll walk away better equipped with strategies to put in place immediately to reduce your risk of paybacks, increased scrutiny, and criminal penalties.
This webcast, presented by Tiffany Ferguson, LMSW, CMAC, ACM, addresses the critical gap in Social Determinants of Health (SDoH) reporting for pediatric populations. While SDoH efforts often focus on adults, this session emphasizes the unique needs of children. Attendees will gain insights into the current state of SDoH, new pediatric Z-codes, and the importance of interdisciplinary collaboration. By understanding and applying pediatric-specific SDoH factors, healthcare professionals can improve data capture, compliance, and care outcomes. This webcast is essential for those looking to enhance their approach to pediatric SDoH reporting and coding.
Join Becky Jacobsen, BSN, RN, MBS, CCS-P, CPC, CPEDC, CBCS, CEMC, VP of CDM, for a webcast addressing oncology service coding challenges. Learn to navigate coding for infusions and injections alongside Evaluation and Management (E/M) services, ensuring compliance and accurate reimbursement. Gain insights into documenting E/M services for oncology patients and determining medical necessity. This webcast is essential to optimize coding practices, maintain compliance, and maximize revenue in oncology care.
Copyright © 2024 ICD10monitor. Powered by MedLearn Media.
Happy National Doctor’s Day! Learn how to get a complimentary webcast on ‘Decoding Social Admissions’ as a token of our heartfelt appreciation! Click here to learn more →
